Pipeline expansion of new products fitting in core competencies- Novel injectable antibiotics and others

CRAM business initiatives

Capital expansion in line with pipeline expansion

2^nd USFDA inspection

Commissioned Biotech Block-7 for Antibiotic Downstream Process. Commissioned Biotech Block-8 to expand fermentation capacity

Entry of MMF & Tacrolimus in US generic market as front runner

Commissioned new ETP plant expanded capacity of 350 M³/ day from 50 M³/ day

1^st USFDA inspection for its Biotech facility

Commissioned Biotech Block-3 & 4 dedicated for semi-synthetics & Downstream process of immunosuppressants

Further expansion of Biotech Block-5 & 6 to double the fermentation capacity

Equity partnership by Matrix Laboratories

Commissioned Biotech Block-2 & started commercial production of Lovastatin

Initiated development & production of 1^st Immunosuppressant- Tacrolimus

Filed first DMF/ COS of Lovastatin

Scrapped small chemical unit & bought Biotech equipments & started production of Amidase Enzyme from E.coli strain

Enzyme capacity expansion from 5MT – 15MT/ yr

Facility expansion of Biotech Block-2 for statin manufacturing